Cargando…

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

BACKGROUND: The clinical relevance of mismatch repair (MMR) status in patients with nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the prognostic role of MMR deficiency in patients with stage I-III colorectal and endometrial cancer. METHODS: Patients with nonme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fountzilas, Elena, Kotoula, Vassiliki, Pentheroudakis, George, Manousou, Kyriaki, Polychronidou, Genovefa, Vrettou, Eleni, Poulios, Christos, Papadopoulou, Eirini, Raptou, Georgia, Pectasides, Eirini, Karayannopoulou, Georgia, Chrisafi, Sofia, Papakostas, Pavlos, Makatsoris, Thomas, Varthalitis, Ioannis, Psyrri, Amanda, Samantas, Epaminontas, Bobos, Mattheos, Christodoulou, Christos, Papadimitriou, Christos, Nasioulas, George, Pectasides, Dimitrios, Fountzilas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555870/ https://www.ncbi.nlm.nih.gov/pubmed/31231557 http://dx.doi.org/10.1136/esmoopen-2018-000474

Ejemplares similares

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
por: Polychronidou, Genovefa, et al.
Publicado: (2018)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018)

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018)

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients
por: Krikelis, Dimitrios, et al.
Publicado: (2013)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
por: Pentheroudakis, George, et al.
Publicado: (2015)

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
por: Zarkavelis, George, et al.
Publicado: (2019)

Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Koumarianou, Anna, et al.
Publicado: (2020)

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
por: Kourea, Helen P., et al.
Publicado: (2022)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012)

Genotyping data of routinely processed matched primary/metastatic tumor samples
por: Kotoula, Vassiliki, et al.
Publicado: (2020)

Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
por: Mountzios, G, et al.
Publicado: (2019)

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2013)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Pectasides, Eirini, et al.
Publicado: (2014)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
por: Fountzilas, Elena, et al.
Publicado: (2018)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

Protein expression patterns of cell cycle regulators in operable breast cancer
por: Zagouri, Flora, et al.
Publicado: (2017)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
por: Razis, Evangelia, et al.
Publicado: (2008)

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma
por: Fountzilas, Elena, et al.
Publicado: (2021)

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group
por: Psyrri, Amanda, et al.
Publicado: (2017)

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
por: Kotoula, Vassiliki, et al.
Publicado: (2016)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ebrf6kdokb1jgdm1m217236ud0